Indian Tarceva effect Indian Tarceva effect manual 13501239552

() The third-line treatment indication of Tarceva in India for locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens is based on the results of the aforementioned foreign phase-1 clinical study. It is concluded that it is suitable for Chinese non-small cell lung cancer. The efficacy of second-line treatment for cellular lung cancer needs to be confirmed by further clinical studies. The results of two multi-center placebo-controlled randomized phase III trials in the first-line treatment of locally advanced or metastatic patients showed that platinum-based chemotherapy (carboplatin + paclitaxel or gemcitabine + Cisplatin) while taking erlotinib is not clinically relevant and is therefore not recommended for use in the above situations. [Usage and Dosage] This product must be used under the guidance of a doctor with experience in the use of such drugs, and is only used at the National Clinical Trial Pharmacology Base. Or used in Class IIIA hospitals.
() Trade name: Tarceva Generic name: Erlotinib hydrochloride Text: Trade name: English generic namebr/> () [Ingredients] Each tablet contains erlotinib (in the form of erlotinib hydrochloride)
() Tarceva, India
() [Properties] Round, biconvex, white coated tablets.
() [Mechanism of action: The anti-tumor mechanism is mainly to inhibit the intracellular phosphorylation of epidermal growth factor tyrosine kinase.
() [Pharmacokinetics: % absorbed after administration, half-life of about 1 hour, mainly eliminated by metabolism. The oral bioavailability is approximately %, and peak plasma concentration is reached after several hours. Pharmacokinetic analysis of the patient receiving monotherapy showed that it takes days to reach stable blood concentration. The patient's age, weight, and gender have no significant relationship with the drug clearance rate. Smoking can increase the drug clearance rate by %.
() [Indications: third-line treatment of locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens.
() [Contraindications] It is prohibited for those who are allergic to this product and its ingredients.
() [Usage and Dosage] This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in the national tumor drug clinical trial base or tertiary A hospitals. The recommended dose of erlotinib monotherapy for non-small cell lung cancer is /day, taken at least one hour before or one hour after eating. Continue treatment until disease progression or intolerable toxicity occurs. There is no evidence that patients benefit from continuing treatment after progression. 【Dosage Instructions】Whether it takes effect depends on the situation. Some patients will have effects on the same day they take Tarceva, while others will see significant improvement within a few days. This varies from person to person and is not the same. There are also patients who get results after taking it for a week, but this is extremely rare. The onset of effect of Tarceva is usually within days. How to test whether Tarceva is effective?
() First, look at the improvement of the patient's symptoms, whether the pain is relieved, whether the spirit is improved, etc. The second is to check with the help of modern technology, that is, imaging, which means to conduct a comparative examination of the lesions after taking Tarceva for a period of time. Whether Tarceva is effective can be clearly seen from the film.
() Men or patients with phosphorus cancer are less effective when taking Tarceva, but it is not completely ineffective. The reason for this misunderstanding is that Tarceva has always placed too much emphasis on individual characteristics such as women and non-smoking. It gives the impression that Tarceva is not suitable for men. In fact, men taking Tarceva can also have the same effect.
() Speaking of Tarceva’s onset of effect, we have to mention Tarceva’s resistance. Tarceva’s resistance, like Tarceva’s onset of action, also varies from person to person. Under normal circumstances, the survival period is another month or a little more, and for some patients, it is normal to develop drug resistance for several months. Some patients even have drug resistance for years, which varies from person to person.